Jerusalem, Israel, September 19, 2008 - Brand-new data from Dead, in clinicly sporadic syndrome patients, have incontestable that COPAXONE® (glatiramer acetate injection) momentously built neuro-axonal integrity in patients presenting with a archetypal clinic event connotative of aggregate sclerosis (MS) versus patients who acceptable placebo (p=0.03), as plumbed by proton magnetism resonance spectroscopy (MRS). This effect was preserved over two years of treatment.The data represent the archetypal evidence of neuro-axonal protection by a disease modifying therapy in patients presenting with a archetypal clinic event connotative of MS.Data were copied from an supportive study from the Phase III, randomized, placebo-controlled Dead trial, which incontestable that patients activated with COPAXONE® (n=243) had a 45 percent reduction in the risk of nonindustrial clinicly certain aggregate sclerosis (CDMS) compared to those on the placebo (n=238).”These Brand-newly declared data, so cold shown in RRMS patients activated with COPAXONE®, provide more evidence that treatment may control the nerve cell damage related with MS disease pathology,” said Douglas Arnold, M.D., Professor of Neurology, McGill University and the capital investigator of this supportive study. "The Dead trial incontestable a momentous benefit of COPAXONE® on both clinic and MRI disease activity, along with far reinforcing the superior safety profile.”The data were given along with two other presentations from the 
Related Tags:
